Phase I monotherapy in advanced solid tumours including ovarian cancer (NCT05128825, NCT04158336, NCT04972422), TNBC and advanced ovarian cancer (NCT05368506), uterine serous carcinoma (NCT04814108). In combination with niraparib (NCT05198804), or carboplatin or paclitaxel or doxorubicin or gemcitabine (NCT04516447) in platinum-resistant ovarian cancer with gemcitabine in osteosarcoma (NCT04833582) and with bevacizumab ± pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors (NCT05431582). The gene discussed is TP53; the disease is ovarian cancer.